🇺🇸Jennifer
Doudna

She was in sixth grade in Hilo, Hawaii, when her father left a copy of James Watson's The Double Helix on her bed. It was a deliberate gift — her father, a professor of literature, had noticed that his daughter was fascinated by science in the way that certain children are fascinated by things that will define their entire lives. Jennifer Doudna read the book in a single sitting. It described a race, a puzzle, a discovery, and a world where the most important questions were molecular. She decided then that she wanted to be a scientist. She could not have known that she would one day win the same Nobel Prize as Watson, for a discovery that made his look like a prologue.

Doudna grew up in Hawaii, studied chemistry at Pomona College, and earned her PhD from Harvard in 1989 under Jack Szostak, a future Nobel laureate, working on RNA catalysis — the then-controversial idea that RNA molecules could function as enzymes. She continued this work at the University of Colorado and then at Yale, building a reputation as one of the world's foremost structural biologists of RNA. When she moved to the University of California, Berkeley in 2002, she was already a member of the National Academy of Sciences. The discovery that made her a household name had not yet begun to take shape.

The story of CRISPR begins not with a grand hypothesis but with a bacterial immune system that microbiologists had been puzzling over for years. Bacteria, it turned out, had a mechanism for remembering viruses that had attacked them before — a kind of molecular memory encoded in repeating sequences of DNA that researchers had named CRISPR, for Clustered Regularly Interspaced Short Palindromic Repeats. In 2011, at a scientific conference in Puerto Rico, Doudna was introduced to Emmanuelle Charpentier, a French microbiologist who had been studying a key protein in this system called Cas9. They began a collaboration within days. Working across the Atlantic — Charpentier in Sweden, Doudna in Berkeley — they spent a year figuring out exactly how Cas9 found its target, cut it, and could be redirected at will.

The paper they published in Science in August 2012 was precise, methodical, and revolutionary. It demonstrated that the Cas9 protein could be programmed with a short guide RNA to find any DNA sequence in any organism and cut it with extraordinary precision — and that the cut could be used to delete, disable, or replace genes. The implications were immediate and staggering. Within months, labs around the world were using the technique in human cells, mouse embryos, plants, insects, fish. Within years, clinical trials had begun for CRISPR-based treatments for sickle cell disease, certain cancers, and forms of blindness. The technology moved from laboratory to clinic faster than almost any tool in the history of medicine.

Doudna has been outspoken about the ethical dimensions of her invention. In 2018, when Chinese scientist He Jiankui announced the birth of the first gene-edited human babies — an experiment conducted in secret without adequate ethical review — Doudna was among the scientists who called most forcefully for a global moratorium on heritable human genome editing. She helped organize an international commission to study the governance of human genome editing and has argued consistently that the technology's power demands commensurate caution. In 2020, the Nobel Committee awarded the Chemistry Prize jointly to Doudna and Charpentier — the first Nobel Prize in Chemistry awarded to two women — for a discovery the committee described as having "rewritten the code of life."